Jump to main content
Jump to site search


Sodium-glucose SGLT-2 cotransporter inhibitors: A new antidiabetic drug class

Abstract

Diabetes mellitus is a chronic, complex and multifactorial disease associated characteristically with hyperglycemia. One of the most recently approved antidiabetic drug class for clinical use comprehends the sodium-glucose cotransporter type 2 (SGLT-2) inhibitors. SGLT-2 is a protein expressed in the kidneys, responsible for glucose reabsorption from the glomerular filtrate to the plasma. It is known, nowadays, that the diabetic patients present an increased glucose renal reabsorption capacity, caused by the overexpression of the SGLT-2 transporter, thus contributing to hyperglycemia. From establishing this correlation, the SGLT-2 transporter started being cosidered as a therapeutic target of interest, culminating in the approval of the first antidiabetic SGLT-2 inhibitor, dapagliflozin (Forxiga® or Farxiga®, Bristol-Myers Squibb & AstraZeneca) in 2012 in Europe. On the other hand, canagliflozin (Invokana®, Janssen Pharmaceutical) was the first drug in this class to be approved by FDA, the U.S. Food and Drug Administration, in 2013. This review concerns the discovery and development of the first representatives in this class of antidiabetic drugs, and the description of new optimized analogues that are currently in the clinical and preclinical stages of development.

Back to tab navigation

Publication details

The article was received on 03 Apr 2018, accepted on 05 Jun 2018 and first published on 06 Jun 2018


Article type: Review Article
DOI: 10.1039/C8MD00183A
Citation: Med. Chem. Commun., 2018, Accepted Manuscript
  •   Request permissions

    Sodium-glucose SGLT-2 cotransporter inhibitors: A new antidiabetic drug class

    P. Nogueira da Silva, R. Alves da Conceição, R. Maia and M. L. D. C. Barbosa, Med. Chem. Commun., 2018, Accepted Manuscript , DOI: 10.1039/C8MD00183A

Search articles by author

Spotlight

Advertisements